Puente-Vallejo Raul, Pacheco María Del Pilar, Muhammad Iqrah
Radiation Oncology Department, Hospital Metropolitano, Quito, ECU.
Palliative Care Department, Hospital Solca Nucleo de Quito, Quito, ECU.
Cureus. 2025 Aug 6;17(8):e89473. doi: 10.7759/cureus.89473. eCollection 2025 Aug.
Lattice radiotherapy (LRT) is a type of spatially fractionated radiation therapy (SFRT) that enables the delivery of ablative doses to specific internal regions of large tumoral lesions, while surrounding tissues and nearby critical structures receive significantly lower exposure. This technique relies on a spatial distribution strategy that allows dose levels of radiation to be applied within the tumor in a single session or, alternatively, over the course of five sessions. Over time, LRT has gained attention as a promising method for managing large tumors, especially in cases where conventional treatments may pose higher risks or be less effective, offering the benefit of reduced side effects. This report details the case of a 67-year-old patient suffering from metastatic kidney cancer with a large retroperitoneal mass, which led to severe abdominal pain and symptoms from compression of the inferior vena cava. The patient was treated with LRT over five sessions. The intervention led to rapid relief of symptoms and, during follow-up, a noticeable reduction in tumor size was observed, contributing to a clear improvement in the patient's daily functioning and quality of life. This clinical experience emphasizes the potential role of LRT in addressing large, hard-to-treat tumors and suggests that it may be an effective palliative option in advanced cases of kidney cancer.
点阵放射疗法(LRT)是一种空间分割放射疗法(SFRT),它能够将消融剂量的辐射传递到大型肿瘤病变的特定内部区域,而周围组织和附近的关键结构所接受的辐射暴露则显著更低。该技术依赖于一种空间分布策略,这种策略允许在单次治疗中或在五个疗程的过程中,将辐射剂量应用于肿瘤内部。随着时间的推移,点阵放射疗法作为一种治疗大型肿瘤的有前景的方法受到了关注,特别是在传统治疗可能带来更高风险或效果较差的情况下,它具有减少副作用的益处。本报告详细介绍了一名67岁患有转移性肾癌且伴有巨大腹膜后肿块的患者的病例,该肿块导致严重腹痛以及下腔静脉受压症状。该患者接受了五个疗程的点阵放射疗法治疗。干预措施使症状迅速缓解,并且在随访期间,观察到肿瘤大小显著缩小,这有助于患者日常功能和生活质量的明显改善。这一临床经验强调了点阵放射疗法在治疗大型难治性肿瘤方面的潜在作用,并表明它可能是晚期肾癌病例中的一种有效姑息治疗选择。